Notice: This company has been marked as potentially delisted and may not be actively trading. (BIOA) (BIOA) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOwnershipTrends BIOA vs. AVDL, SEPN, PLRX, VERV, CAPR, ABUS, BCAX, DNTH, KURA, and PHARShould you be buying (BIOA) stock or one of its competitors? The main competitors of (BIOA) include Avadel Pharmaceuticals (AVDL), Septerna (SEPN), Pliant Therapeutics (PLRX), Verve Therapeutics (VERV), Capricor Therapeutics (CAPR), Arbutus Biopharma (ABUS), Bicara Therapeutics (BCAX), Dianthus Therapeutics (DNTH), Kura Oncology (KURA), and Pharming Group (PHAR). These companies are all part of the "pharmaceutical preparations" industry. (BIOA) vs. Avadel Pharmaceuticals Septerna Pliant Therapeutics Verve Therapeutics Capricor Therapeutics Arbutus Biopharma Bicara Therapeutics Dianthus Therapeutics Kura Oncology Pharming Group Avadel Pharmaceuticals (NASDAQ:AVDL) and (BIOA) (NYSE:BIOA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation and community ranking. Does the media favor AVDL or BIOA? In the previous week, (BIOA) had 27 more articles in the media than Avadel Pharmaceuticals. MarketBeat recorded 33 mentions for (BIOA) and 6 mentions for Avadel Pharmaceuticals. Avadel Pharmaceuticals' average media sentiment score of 1.11 beat (BIOA)'s score of 0.00 indicating that Avadel Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avadel Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive (BIOA) 2 Very Positive mention(s) 3 Positive mention(s) 27 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger earnings and valuation, AVDL or BIOA? (BIOA) has lower revenue, but higher earnings than Avadel Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvadel Pharmaceuticals$138.16M5.51-$160.28M-$0.79-10.00(BIOA)N/AN/AN/AN/AN/A Does the MarketBeat Community favor AVDL or BIOA? Avadel Pharmaceuticals received 55 more outperform votes than (BIOA) when rated by MarketBeat users. However, 72.75% of users gave (BIOA) an outperform vote while only 66.28% of users gave Avadel Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAvadel PharmaceuticalsOutperform Votes34666.28% Underperform Votes17633.72% (BIOA)Outperform Votes29172.75% Underperform Votes10927.25% Is AVDL or BIOA more profitable? (BIOA) has a net margin of 0.00% compared to Avadel Pharmaceuticals' net margin of -52.53%. (BIOA)'s return on equity of 0.00% beat Avadel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Avadel Pharmaceuticals-52.53% -93.34% -44.77% (BIOA) N/A N/A N/A Do analysts rate AVDL or BIOA? Avadel Pharmaceuticals currently has a consensus price target of $21.00, indicating a potential upside of 165.82%. (BIOA) has a consensus price target of $6.33, indicating a potential upside of 38.13%. Given Avadel Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Avadel Pharmaceuticals is more favorable than (BIOA).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avadel Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00(BIOA) 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Do insiders & institutionals have more ownership in AVDL or BIOA? 69.2% of Avadel Pharmaceuticals shares are held by institutional investors. 4.8% of Avadel Pharmaceuticals shares are held by company insiders. Comparatively, 1.8% of (BIOA) shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryAvadel Pharmaceuticals beats (BIOA) on 8 of the 13 factors compared between the two stocks. Get (BIOA) News Delivered to You Automatically Sign up to receive the latest news and ratings for BIOA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIOA vs. The Competition Export to ExcelMetric(BIOA)Pharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$178.17M$6.85B$5.57B$20.09BDividend YieldN/A2.90%5.32%3.64%P/E RatioN/A9.7489.4242.56Price / SalesN/A301.931,253.4018.56Price / CashN/A73.5045.9620.47Price / BookN/A5.275.125.90Net IncomeN/A$136.98M$111.33M$1.02B (BIOA) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIOA(BIOA)0.7433 of 5 stars$4.59-1.2%$6.33+38.1%+35,720.3%$178.17MN/A0.00N/AAVDLAvadel Pharmaceuticals3.301 of 5 stars$7.49-4.6%$21.00+180.6%-45.1%$722.12M$27.96M-9.4970Analyst RevisionPositive NewsSEPNSepternaN/A$16.15-12.6%$43.67+170.4%N/A$717.10MN/A0.00N/APLRXPliant Therapeutics3.901 of 5 stars$11.00+0.7%$40.50+268.3%-40.0%$669.05M$1.58M-3.2990VERVVerve Therapeutics2.2974 of 5 stars$7.75-2.0%$25.75+232.2%-29.7%$658.74M$11.76M-3.16110CAPRCapricor Therapeutics1.9851 of 5 stars$14.25-3.8%$34.50+142.2%+272.3%$647.72M$25.18M-13.44N/AABUSArbutus Biopharma2.7077 of 5 stars$3.42+2.9%$5.50+61.1%+40.5%$647.11M$18.14M-7.9490BCAXBicara TherapeuticsN/A$11.62+0.1%$43.75+276.5%N/A$632.36MN/A0.0032Gap UpDNTHDianthus Therapeutics1.9412 of 5 stars$21.10-0.5%$46.43+120.0%+16.6%$624.68M$2.83M-8.4480Short Interest ↑KURAKura Oncology4.663 of 5 stars$7.92-0.8%$27.38+245.9%-60.7%$615.47MN/A-3.35130Short Interest ↓PHARPharming Group2.9723 of 5 stars$9.01-1.0%$27.00+199.7%-31.3%$611.19M$285.75M-34.65280Short Interest ↑ Related Companies and Tools Related Companies Avadel Pharmaceuticals Alternatives Septerna Alternatives Pliant Therapeutics Alternatives Verve Therapeutics Alternatives Capricor Therapeutics Alternatives Arbutus Biopharma Alternatives Bicara Therapeutics Alternatives Dianthus Therapeutics Alternatives Kura Oncology Alternatives Pharming Group Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:BIOA) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredElon’s ultimate power move?THE ELON SHOCK All of Elon Musk’s strange behavior may soon make sense… and impact the markets in a way no ...Altimetry | SponsoredNew catalyst on Wall Street’s radar for this week (NOT Trump)Wall Street is already looking past Trump… To a new catalyst on the near horizon that could be even bigger ...Timothy Sykes | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (BIOA) Please log in to your account or sign up in order to add this asset to your watchlist. Share (BIOA) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BIOA Stock Alerts